Parathyroid hormone (PTH) secretion is regulated by a cell surface Ca 2؉ receptor that detects small changes in the level of plasma Ca 2؉ . Because this G protein-coupled receptor conceivably provides a distinct molecular target for drugs useful in treating bone and mineral-related disorders, we sought to design small organic molecules that act on the Ca 2؉ receptor. We discovered that certain phenylalkylamine compounds, typified by NPS R-568 and its deschloro derivative NPS receptor are termed calcimimetics. The discovery of calcimimetic compounds with potent and selective activity enables a pharmacological approach to regulating plasma levels of PTH. Calcimimetic compounds could conceivably provide a specific medical therapy for primary hyperparathyroidism.
The concentration of ionized calcium (Ca 2ϩ ) in plasma is regulated largely by parathyroid hormone (PTH), which acts on the kidney and on bone to increase the level of plasma Ca ] i ) gave rise to the hypothesis that parathyroid cells express a cell surface Ca 2ϩ receptor that enables these cells to detect and respond to small changes in the concentration of extracellular Ca 2ϩ (1, 2) . Subsequent studies supported the existence of a Ca 2ϩ receptor (for review, see ref. 3) , and the hypothesis has now been confirmed by the recent cloning of a cDNA encoding a Ca 2ϩ receptor from bovine (4) and human (5) parathyroid cells.
The Ca 2ϩ receptor is a member of the G protein-coupled receptor superfamily and possesses an unusually large extracellular domain, the characteristic seven transmembrane domain, and a relatively long cytoplasmic tail. In these topological aspects, the Ca 2ϩ receptor is similar to metabotropic glutamate receptors (mGluR), although the sequence homology between these receptors is only about 25%. The human (1,078 amino acids) and bovine (1,085 amino acids) parathyroid cell Ca 2ϩ receptors are glycosylated proteins of ϳ120 kDa and are 93% identical (5) . The Ca 2ϩ receptor expressed on authentic parathyroid cells or in heterologous cellular systems couples to phospholipase C and, when activated by increased concentrations of extracellular Ca 2ϩ , elicits rapid increases in inositol 1,4,5-trisphosphate and [Ca 2ϩ ] i (2, 4, 6) . Thus, in its functional and structural properties, the parathyroid Ca 2ϩ receptor is akin to other cell surface receptors that initially transduce extracellular signals into functional cellular responses. The difference is that the physiological ligand for the Ca 2ϩ receptor is an inorganic ion, rather than an organic molecule.
G protein-coupled receptors have been a classic site of action for drugs useful in treating various diseases. As a member of the G protein-coupled receptor superfamily, the Ca 2ϩ receptor is seemingly an ideal target for new pharmaceuticals useful in treating disorders of bone and mineral metabolism, such as hyperparathyroidism and osteoporosis. At present, however, the only ligands known to act on the Ca 2ϩ receptor are other inorganic di-and trivalent cations (2, 7) and organic polycations (8) (9) (10) that are nonselective and lack utility as systematic therapeutics. The present report describes the results of our initial efforts to devise a small organic compound that selectively acts on the parathyroid Ca 2ϩ receptor yet lacks a polycationic structure. NPS R-467 and NPS R-568 ( Fig. 1) are two compounds that emerged from this effort. They are potent and selective activators of the Ca 2ϩ receptor and inhibit PTH secretion in vitro. Such an action defines a new class of pharmacological agents and suggests an entirely novel approach to treating hyperparathyroidism. An XhoI(blunted)-BamHI fragment of the rat mGluR1a cDNA was subcloned into the mammalian expression vector pCEP4 containing hygromycin as a selectable marker. This plasmid was transfected into HEK 293 cells by using Lipofectamine (GIBCO͞BRL). Cells were grown in DMEM (without L-glutamine) supplemented with 10% dialyzed fetal bovine serum and hygromycin (200 g͞ml).
MATERIALS AND METHODS

Buffers
For measurements of [Ca 2ϩ ] i , the cells were recovered from tissue culture flasks by brief treatment with 0.02% EDTA and then washed and resuspended in PCB containing 1 mM CaCl 2 and 0.1% BSA. The cells were loaded with fluo-3 by incubation for 30 min at 37°C, with PCB containing 0.5% BSA in 1 mM CaCl 2 and 2 M fluo-3 acetoxymethyl ester. The cells were subsequently washed and fluorescence was recorded by using excitation and emission wavelengths of 485 and 530 nm, respectively.
Studies with Xenopus Oocytes. Oocytes were isolated from adult female Xenopus laevis toads and injected with 5 ng of cRNA encoding either the human mGluR8 or human mGluR2 plus 1 ng of G protein-coupled inwardly rectifying K ϩ channel (GIRK) and 1 ng of cardiac inwardly rectifying K ϩ channel (CIR) cRNA and incubated at 16°C in MBS for 3 or 4 days prior to electrophysiological recording (13) . MBS contained 88 mM NaCl, 1 mM KCl, 0.82 mM MgSO 4 , 10 mM Hepes, and 2.4 mM NaCO 3 (pH, 7.5). Oocytes were voltage-clamped at a holding potential of Ϫ90 mV by using standard two-electrode voltage-clamp techniques, and currents were recorded on a chart recorder. The standard control buffer was ND96 (96 mM NaCl͞4 mM KCl͞5 mM Hepes͞1 mM CaCl 2 ͞1 mM MgCl 2 , pH 7.5). All substances were added by bath superfusion at a flow rate of about 5 ml͞min. Prior to application of test substances, the oocytes were allowed to equilibrate in a high potassium solution (HK25) containing 25 mM KCl and 75 mM NaCl. Activation of mGluR2 or mGluR8 through GIRK͞ CIR was quantified by measuring the peak inward current, relative to the holding current at Ϫ90 mV.
Synthetic Chemistry. NPS 568 was prepared by the condensation of 3Ј-methoxyacetophenone with 3-(2Ј-chlorophenyl)-1-propylamine in the presence of titanium in isopropoxide. Reduction of the intermediate imine was accomplished with sodium cyanoborohydride in ethanol. Standard work-up followed by silica gel chromatrography afforded NPS 568 in 96% yield. NPS 467 was prepared in a similar fashion starting with 3-phenyl-1-propylamine. Enantiomers of both compounds were resolved with chiral HPLC (ChiralCel OD; 25 ϫ 2 cm), and the hydrochloride salt of each enantiomer was prepared by treatment of the free base with anhydrous HCl in diethyl ether.
Structural analysis was by GC-MS, 1 H NMR, 13 C NMR, and combustion analysis. Optical purity (Ͼ99.5%) was assessed by chiral HPLC. The structure and absolute configuration of NPS R-568⅐HCl were confirmed by x-ray crystallography.
Data Presentation and Analysis. The concentrations reported are for the free base of NPS R-467 and NPS R-568. To determine 
RESULTS
To screen for agonist-like activity on the Ca 2ϩ receptor, we assessed the ability of test substances to evoke an increase in [Ca 2ϩ ] i in bovine parathyroid cells. Screening of phenylalkylamine-type compounds revealed that fendiline caused a large increase in [Ca 2ϩ ] i (EC 50 ϭ 12 M); and this compound served as the starting point for structural modifications. Out of a number of analogs synthesized and tested, NPS 568 and its deschloro derivative NPS 467 (Fig. 1) were selected for detailed pharmacological profiling.
The racemic mixtures of NPS 568 and NPS 467 were resolved into the R and S enantiomers and each isomer was tested for its ability to increase [Ca 2ϩ ] i in bovine parathyroid cells. Both isomers caused concentration-dependent increases in [Ca 2ϩ ] i . The R enantiomer of NPS 467 was about 100-fold more potent than the corresponding S enantiomer ( Fig. 2A) , and the R enantiomer of NPS 568 was about 10-fold more potent than its corresponding enantiomer (data not shown). When tested on HEK 293 cells expressing the human parathyroid Ca 2ϩ receptor (HEK 293 4.0-7 cells), both isomers caused increases in [Ca 2ϩ ] i . Again, the R enantiomers were 10-to 100-fold more potent than the S enantiomers (Fig. 2B) . In both cell types, NPS R-568 was about twice as potent as NPS R-467.
In parathyroid cells, the increase in [Ca 2ϩ ] i elicited by extracellular Ca 2ϩ arises from the mobilization of intracellular Ca 2ϩ and the influx of extracellular Ca 2ϩ through voltage-insensitive channels (2, 14) . The pattern of change of [Ca 2ϩ ] i elicited by NPS R-467 or NPS R-568 in bovine parathyroid cells was similar to that evoked by extracellular Ca 2ϩ and consisted of a rapid and transient increase followed by a lower yet sustained increase in [Ca 2ϩ ] i (Fig. 3 A and B (Fig. 3 C and D) . This suggests that the transient increase in [Ca 2ϩ ] i elicited by NPS R-467 or NPS R-568, ] i under these conditions (Fig. 3E) . The phenylalkylamine compounds were similarly without effect on [Ca To further investigate the mechanism of action of these compounds, concentration-response curves to extracellular Ca 2ϩ in the presence and absence of NPS R-467 or NPS R-568 were determined in bovine parathyroid cells. In the absence of NPS R-568, increasing the concentration of extracellular Ca 2ϩ caused progressive increases in [Ca 2ϩ ] i and did so with an EC 50 of 1.66 Ϯ 0.34 mM. The addition of NPS R-568 (100 nM) shifted the concentration-response curve for extracellular Ca 2ϩ to the left without affecting the maximal response and, thereby, decreased the EC 50 value for extracellular Ca 2ϩ to 0.61 Ϯ 0.04 mM (Fig. 4A) . At these concentrations, NPS R-568 failed to elicit increases in [Ca 2ϩ ] i when extracellular Ca 2ϩ was Յ0.5 mM or have further stimulating effects when levels of extracellular Ca 2ϩ were Ն1.5 mM. Essentially identical results were obtained with NPS R-467 or when either compound was studied under the same experimental conditions with HEK 293 4.0-7 cells. These compounds therefore potentiate the cytoplasmic Ca 2ϩ response to extracellular Ca 2ϩ .
Both compounds inhibited secretion of PTH in a concentration-dependent and stereoselective manner. In bovine parathyroid cells, the inhibitory effects of NPS R-568 on PTH secretion were seen at concentrations as low as 3 nM and the IC 50 was 27 Ϯ 7 nM. NPS R-467 also inhibited PTH secretion at concentrations Ն10 nM. The S enantiomer of NPS R-467 or NPS R-568 did not affect secretion of PTH even when tested at concentrations as high as 1 M. This is shown for NPS 568 in Fig. 4B . Significantly, the magnitude of inhibition (70-80%) achieved with NPS R-568 was just as great as that caused by the physiological ligand, extracellular Ca 2ϩ (Fig. 4B) .
As with the effect of these compounds on [Ca 2ϩ ] i , their effects on the secretion of PTH was abolished at low levels of extracellular Ca 2ϩ . Rather, both compounds augmented the inhibitory effects of extracellular Ca 2ϩ , thereby shifting the concentrationresponse curve for extracellular Ca 2ϩ to the left (Fig. 4C) responses elicited by submaximal concentrations of bradykinin, thrombin, or ATP were neither augmented nor depressed by high concentrations (10 M) of NPS R-467 or NPS R-568 (Fig. 5 A and B) . Nor did these compounds affect the cytoplasmic Ca 2ϩ response to ATP in bovine parathyroid cells. This P2Y-purinergic receptor, like the Ca 2ϩ receptor, is coupled to the mobilization of intracellular Ca 2ϩ in parathyroid cells (15) . Yet ATP (100 M) elicited essentially identical increases in [Ca 2ϩ ] i in both the presence (156 Ϯ 33% increase over basal [Ca 2ϩ ] i ) and absence of 100 nM NPS R-568 (163 Ϯ 37% increase; n ϭ 3). Moreover, the concentration-response curve to ATP (3-100 M) in parathyroid cells was similar in the presence and the absence of 300 nM NPS R-467.
Although the above findings indicate that NPS R-467 and NPS R-568 do not affect a number of other structurally diverse G protein-coupled receptors, a more rigorous test of selectivity would be to examine the effects of these compounds on G protein-coupled receptors that are structurally related to the receptor. The G protein-coupled receptors that share significant homology with the Ca 2ϩ receptor are the mGluRs. Group I mGluRs (mGluR1 and mGluR5), like the Ca 2ϩ receptor, couple to phospholipase C and, when activated, elicit the mobilization of intracellular Ca 2ϩ (16) . We therefore tested for the effects of these compounds on the cytoplasmic Ca 2ϩ responses elicited by glutamate in HEK 293 cells expressing the rat mGluR1a. In these cells, glutamate elicits a rapid increase in [Ca 2ϩ ] i that arises from the mobilization of intracellular Ca 2ϩ ( Fig. 5 C and D) . Treatment with NPS R-568 did not evoke an increase in [Ca 2ϩ ] i nor did it affect the cytoplasmic Ca 2ϩ responses elicited by the subsequent addition of glutamate in these mGluR1a-expressing cells.
Group II (mGluR2 and mGluR3) and group III receptors (mGluR4, mGluR6, mGluR7, and mGluR8) do not couple effectively to the mobilization of intracellular Ca 2ϩ but do activate GIRK when expressed in Xenopus oocytes (13) . Phenylalkylamine compounds were therefore examined for effects on glutamate-evoked currents in Xenopus oocytes expressing mGluR2 or mGluR8 and GIRK͞CIR. Maximal responses to L-glutamate were obtained at 30 M in oocytes expressing mGluR2 and at 10 M in those expressing mGluR8. Submaximal concentrations of glutamate elicited an inward K ϩ current in oocytes that was either partially (for mGluR2) or totally blocked (for mGluR8) by the glutamate receptor antagonist (R,S)-␣-cyclopropyl-4-phosphonophenylglycine ( Fig. 6 A and B) . By itself, 10 M NPS R-467 caused a small inhibition of the basal K ϩ current (10 Ϯ 2% inhibition, n ϭ 6) that was not dependent on expression of either mGluR2 or mGluR8. However, even this relatively high concentration of NPS R-467 was without effect on glutamate-evoked responses in oocytes expressing mGluR2 and only slightly inhibited evoked responses in those expressing mGluR8 (10 Ϯ 6% inhibition, n ϭ 4; Fig. 6 C and D) . Similar results were obtained with 10 M NPS R-568. The phenylalkylamine compounds thus appear to lack activity at mGluRs. is the primary physiological ligand activating the Ca 2ϩ receptor, a variety of di-and trivalent cations and organic polycations can also act as ligands at this receptor and decrease secretion of PTH (2, (7) (8) (9) (10) . Polycationic ligands, however, are of limited utility as pharmacological probes of the Ca 2ϩ receptor because they lack specificity and͞or potency. Inorganic and organic polycations are clearly unsuitable for altering plasma levels of PTH in disease states. Indeed, it has been uncertain whether pharmaceutically useful compounds acting on the Ca 2ϩ receptor could be designed, because the atomic nature of the physiological ligand provides essentially no structural insight into the type of compounds that might act on this receptor. The present results provide evidence that potent and selective small organic compounds that lack a polycationic structure yet retain activity on the Ca 2ϩ receptor can be devised.
Phenylalkylamine compounds like NPS R-467 or NPS R-568 do not elicit cytoplasmic Ca 2ϩ responses in wild-type HEK 293 cells but do so in HEK 293 cells expressing the Ca 2ϩ receptor. Either these compounds directly activate the Ca 2ϩ receptor or they affect some transmembrane signaling mechanism peculiar to the Ca 2ϩ receptor. This putative signaling mechanism cannot couple to receptors for thrombin, bradykinin, or ATP because the phenylalkylamine compounds neither elicit nor block cytoplasmic Ca 2ϩ responses in wild-type cells expressing these receptors. Similarly, this presumed signaling mechanism is not peculiar to expression of a nonnative receptor because cells transfected with mGluR1a also do not respond to the phenylalkylamine compounds. The most parsimonious view supposes that NPS R-467 and NPS R-568 act directly on the Ca 2ϩ receptor.
To the extent studied so far, the effects of the phenylalkylamine compounds on parathyroid cell function parallel those of extracellular Ca 2ϩ ; i.e., they elicit increases in [Ca 2ϩ ] i that arise from the mobilization of intracellular Ca 2ϩ and the influx of extracellular Ca 2ϩ and they inhibit the secretion of PTH. Preliminary results suggest that these phenylalkylamine compounds also block ␤-adrenergic receptor-induced increases in cAMP formation in a pertussis toxin-sensitive manner (M.E.S. and E.F.N., unpublished data) as does extracellular Ca 2ϩ (17) . Despite these parallels, the molecular mechanism of action of the phenylalkylamine compounds differs from that of extracellular Ca 2ϩ and other polycations. Unlike the inorganic and organic polycations, the activity of the phenylalkylamine compounds is dependent on the presence of extracellular Ca 2ϩ or some substitute polycation. The ability of the phenylalkylamine compounds to shift the concentration-response curves for extracellular Ca 2ϩ without affecting the maximal responses suggests that these compounds act as allosteric effectors and not as conventional receptor agonists.
Phenylalkylamine compounds are known to interact with a number of different molecular targets. Nonetheless, NPS R-467 and NPS R-568, despite their relatively simple structure, do not affect responses to a variety of other G protein-coupled receptors. Particularly noteworthy is their failure to affect responses to a representative receptor from each of the three groups of mGluRs. Of all structurally characterized G protein-coupled receptors, these are the most homologous to the Ca 2ϩ receptor. In testing for activity on other G protein-coupled receptors, submaximal concentrations of agonist (usually an EC 80 ) were used, so it is unlikely that these phenylalkylamines acted as agonists, antagonists, or allosteric modulators at these other receptors.
The structure of the phenylalkylamine compounds, their potency, selectively, and mechanism of action are features that define a new class of pharmacological compounds. These structural and pharmacodynamic properties are significant improvements over existing Ca 2ϩ receptor ligands. Ligands that mimic or potentiate the effects of extracellular Ca 2ϩ at the Ca 2ϩ receptor have been termed calcimimetics (18) . The phenylalkylamine compounds define a distinct subclass called type II calcimimetics. Type II calcimimetics, typified by NPS R-467 and NPS R-568, suggest a fundamentally new therapeutic approach to the treatment of bone and mineral-related disorders. Compounds of this sort might provide a novel means of controlling plasma levels of PTH in disease states. Because they decrease the secretion of PTH, type II calcimimetic compounds conceivably provide a new therapeutic approach to the management of both primary and secondary hyperparathyroidism. Indeed, a small study has recently demonstrated that orally administered NPS R-568 lowers plasma levels of PTH and Ca 2ϩ in postmenopausal women with mild primary hyperparathyroidism (19) . Thus, calcimimetic compounds may provide the first medical therapy for primary hyperparathyroidism, a disease that has so far resisted pharmacological intervention.
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